Kyverna Therapeutics, Inc.
KYTX
$3.78
-$0.03-0.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 5.72% | -19.06% | -8.69% | -19.75% | -7.90% |
| Total Depreciation and Amortization | 2.79% | -11.01% | 0.90% | 5.28% | 9.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -0.93% | 930.18% | -114.18% | 484.52% | -112.28% |
| Change in Net Operating Assets | 476.69% | -6,523.53% | -99.35% | 19.17% | 339.83% |
| Cash from Operations | 28.87% | -21.19% | -34.82% | -13.71% | 5.29% |
| Capital Expenditure | -- | -- | -421.57% | 90.08% | -89.32% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 422.97% | -81.25% | 3,724.42% | 101.16% | 45.32% |
| Cash from Investing | 422.89% | -80.91% | 4,222.78% | 101.00% | 44.73% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 23.17% | -38.06% | -2.07% | -2.54% | -2.16% |
| Issuance of Common Stock | -100.00% | -90.63% | -64.44% | 23.29% | -99.98% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -342.11% | -- | -- | 100.00% | 86.26% |
| Cash from Financing | -56.76% | -92.56% | -41.45% | 73.29% | -100.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 91.37% | -393.56% | 70.13% | 70.90% | -148.86% |